TransCon CNP matches BioMarin's Voxzogo for achondroplasia with plans for regulatory filings in 2025, showing potential for ...

Ascendis Pharma boasts several commercial stage products. Read why ASND stock is an interesting speculative investment ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Ascendis Pharma (ASND – Research Report). The associated ...

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a ...

The discussions at the event focused on several key topics, including the initiation of legal action by BioMarin Pharmaceutical (NASDAQ:BMRN) Inc. against Ascendis in Europe over a CNP patent, the ...

Goldman Sachs analysts remain positive about the early launch metrics for Yorvipath and its commercial prospects, which they believe could alleviate concerns regarding the performance of Skytrofa.

“Ascendis is well-positioned for rapid revenue growth with the launch of our first two Endocrinology Rare Disease medicines, SKYTROFA and YORVIPATH, and, following our pre-NDA meeting, planned filings ...